| In millions, except per share items | Sep-30-12 | Sep-30-11 | Sep-30-10 | Sep-30-09 | Sep-30-08 | Sep-30-07 | Sep-30-06 | Sep-30-05 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Biopharmaceutical Products and Services | | | | | 14.3 | 13.7 | | |
| Specialty Pharmaceuticals | | | | | 1.7 | 4.5 | | |
| Total revenues [+] | 4.1 | 4.0 | 5.4 | 10.6 | 15.9 | 18.3 | 25.1 | 25.2 |
| Products | 3.0 | 2.4 | 4.2 | | | | | |
| Services | 0.8 | 1.3 | 1.2 | | | | | |
| Revenue growth [+] | 2.5% | -26.1% | -49.3% | -26.0% | -12.9% | -27.0% | -0.5% | -2.9% |
| Biopharmaceutical Products and Services | | | | | 3.8% | | | |
| Specialty Pharmaceuticals | | | | | -63.6% | | | |
| Cost of goods sold [+] | 2.8 | 2.5 | 2.9 | 7.8 | 9.7 | 8.7 | 8.4 | 8.2 |
| Cost of product sales | 1.9 | 1.5 | 2.0 | | | | | |
| Cost of services | 0.9 | 1.0 | 0.9 | | | | | |
| Gross profit | 1.3 | 1.5 | 2.5 | 2.7 | 6.3 | 9.6 | 16.7 | 17.0 |
| Gross margin | 31.7% | 37.1% | 45.8% | 25.8% | 39.8% | 52.3% | 66.5% | 67.3% |
| Selling, general and administrative [+] | 7.5 | 20.4 | 4.3 | 7.5 | 24.1 | 27.7 | 37.3 | 36.3 |
| Sales and marketing | 0.1 | 0.1 | 0.1 | 0.1 | 6.0 | 8.4 | 14.0 | 15.2 |
| General and administrative [+] | 7.4 | 20.2 | 4.2 | 8.1 | 18.1 | 19.3 | 23.3 | 21.1 |
| General and administrative expenses | 7.4 | 20.2 | 4.2 | | | | | |
| Professional fees | -0.1 | -0.4 | -1.1 | | | | | |
| Other selling, general and administrative | | | | -0.8 | | | | |
| Research and development | 5.2 | 2.2 | 1.3 | 1.3 | 8.9 | 15.5 | 14.0 | 9.6 |
| Other operating expenses | -3.8 | -0.1 | 0.0 | 0.8 | 9.5 | 5.6 | 2.0 | 3.0 |
| EBITDA [+] | -7.4 | -20.4 | -2.6 | -6.4 | -25.0 | -37.7 | -33.8 | -28.8 |
| EBITDA growth | -63.6% | 680.6% | -58.8% | -74.6% | -23.6% | 11.5% | 17.5% | 62.0% |
| EBITDA margin | -183.5% | -516.5% | -48.9% | -60.2% | -157.1% | -206.0% | -134.8% | -114.1% |
| Depreciation | 0.1 | 0.1 | 0.3 | 0.2 | 0.7 | 0.6 | 0.7 | 0.7 |
| EBITA | -7.6 | -20.5 | -2.9 | -6.6 | -25.7 | -38.2 | -34.5 | -29.5 |
| EBITA margin | -187.1% | -519.1% | -54.0% | -62.5% | -161.5% | -209.1% | -137.6% | -116.9% |
| Amortization of intangibles | 0.1 | 0.5 | 0.3 | 0.2 | 1.1 | 1.0 | 2.2 | 2.4 |
| EBIT [+] | -7.7 | -21.0 | -3.2 | -6.8 | -26.8 | -39.3 | -36.6 | -31.9 |
| EBIT growth | -63.4% | 554.0% | -53.0% | -74.5% | -22.2% | 7.2% | 14.8% | 57.1% |
| EBIT margin | -189.6% | -530.7% | -59.9% | -64.7% | -168.2% | -214.8% | -146.1% | -126.7% |
| Non-recurring items [+] | 3.8 | 0.2 | 0.4 | 1.5 | 9.5 | 2.4 | 3.3 | 0.4 |
| Asset impairment | | | 0.4 | 1.5 | 9.5 | 3.6 | | |
| Loss (gain) on sale of assets | 3.8 | 0.2 | | | | | | |
| Interest expense | 7.9 | 8.1 | 16.7 | | 28.1 | 19.3 | | |
| Interest expense | 7.9 | 8.1 | 16.7 | | 28.1 | 19.3 | | |
| Other income (expense), net [+] | 7.0 | 13.4 | -27.1 | 3.1 | 3.5 | -15.0 | | |
| Reorganization items | 5.6 | 12.4 | -1.1 | | | | | |
| Gain (loss) on debt retirement | 5.7 | 12.7 | 0.1 | | | | | |
| Other | 0.0 | 0.0 | -0.6 | | | | | |
| Pre-tax income | -12.4 | -15.8 | -47.4 | -5.3 | -60.8 | -76.0 | -43.4 | -44.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% |
| Minority interest | 4.9 | 4.1 | 0.4 | | | | | |
| Earnings from continuing ops | -4.3 | -11.6 | -50.1 | -5.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Earnings from discontinued ops | | | | 1.7 | | | | |
| Net income | -4.3 | -11.6 | -50.1 | -5.3 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net margin | -106.6% | -292.0% | -936.0% | -49.9% | 0.0% | 0.0% | 0.0% | 0.0% |
| |
| Basic EPS [+] | ($0.05) | ($0.17) | ($0.86) | | $0.00 | $0.00 | $0.00 | $0.00 |
| Growth | -68.3% | -80.5% | | | -53.2% | 14.8% | -97.1% | -100.0% |
| Diluted EPS [+] | ($0.05) | ($0.17) | ($0.86) | | $0.00 | $0.00 | $0.00 | $0.00 |
| Growth | -68.3% | -80.5% | | | -53.2% | 14.8% | -97.1% | -100.0% |
| |
| Shares outstanding (basic) [+] | 80.7 | 68.4 | 58.0 | | 45.9 | 34.4 | 27.9 | 5.1 |
| Growth | 18.0% | 17.9% | | | 33.3% | 23.4% | 441.9% | 5.6% |
| Shares outstanding (diluted) [+] | 80.7 | 68.4 | 58.0 | | 45.9 | 34.4 | 27.9 | 5.1 |
| Growth | 18.0% | 17.9% | | | 33.3% | 23.4% | 441.9% | 5.6% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |